Lipocine Inc.
LPCNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 22, 2026 | H.C. Wainwright | Yi Chen | $4.00(+79%) | $2.24 | StreetInsider |
| Apr 13, 2026 | Industrial Alliance Securities | $6.00(+152%) | $2.38 | TheFly | |
| Jan 21, 2026 | H.C. Wainwright | $15.00(+51%) | $9.92 | TheFly | |
| Sep 24, 2024 | Industrial Alliance Securities | Scott Henry | $10.00(+120%) | $4.54 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Neutral | Sep 21, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Apr 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 21, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 27, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 10, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Jul 27, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 26, 2021 |
| Cantor Fitzgerald | maintain | Overweight | Jun 24, 2021 |
| HC Wainwright & Co. | maintain | Buy | May 27, 2021 |
| Ladenburg Thalmann | upgrade | Neutral →Buy | Dec 10, 2020 |
| HC Wainwright & Co. | maintain | Buy | May 27, 2020 |
| Seaport Global | maintain | Buy | Mar 29, 2018 |
| Empire Asset Management | upgrade | Hold →Buy | Feb 27, 2018 |
| Canaccord Genuity | downgrade | Buy →Hold | Jan 11, 2018 |
| H.C. Wainwright | maintain | Buy | Oct 7, 2016 |
| Empire Asset Management | maintain | Buy | Aug 12, 2015 |
| Roth Capital | maintain | Buy | Jul 22, 2015 |
| Evercore ISI Group | maintain | Buy | Jul 16, 2015 |
| Canaccord Genuity | maintain | Buy | Jun 23, 2015 |
Earnings History
Next report: Mar 8, 2027 · EPS est. $-0.33| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.08 | $-0.39 | $2.3M | $159.5K |
| Aug 4, 2026 | $-0.32 | $-0.40 | $190.1K | $213.0K |
| May 7, 2026 | $-0.54 | $-0.51 | $1.2M | $162.5K |
| Mar 9, 2026 | $-0.34 | $-0.60 | $1.1M | $116.0K |
| Nov 6, 2025 | $-0.59 | $-0.56 | $114.6K | $238.0K |
| Aug 5, 2025 | $-0.41 | $-0.41 | $622.8K | $238.0K |
| May 8, 2025 | $-0.35 | $-0.35 | $93.9K | $352.0K |
| Mar 13, 2025 | $0.33 | $-0.40 | $3.5M | $2.6M |
News
SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) In September 2026, Lipocine announced the initiation of the BLOOM (Brexanolone Lifting Outcomes of Moms) study.
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Health Canada has given the go-ahead to Lipocine Inc. (NASDAQ:LPCN) and its licensing partner, Verity Pharmaceuticals Inc., for TLANDO (testosterone undecanoate) capsules.
SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Ve…
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026 Company expects existing resources to support BLOOM SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced the initiation o…
SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C.